Header Logo

Connection

Peter Heydemann to Dystrophin

Back to Details
This is a "connection" page, showing publications Peter Heydemann has written about Dystrophin.
Peter Heydemann
Connection Strength
0.037
Dystrophin
  1. Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017 09 23; 390(10101):1489-1498.
    View in: PubMed
    Score: 0.037
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.